Palomid529inhibitsmTORC1/2andexhibitsanticancerchemotherapeuticandanti-angiogenicactivities.Palomid529iscurrentlyinclinicaltrialsasapotentialtreatmentformaculardegeneration.InmicewithBRCA-1-deficientbreastcancertumors,palomid529inhibitstumorgrowth.Palomid529alsoinhibitsangiogenesisandvascularpermeABIlityincellularmodels.Additionally,palomid529indirectlyinhibitsdownstreamAktsignaling.
| CasNo. | 914913-88-5 |
|---|---|
| Purity | ≥98% |
| Formula | C24H22O6 |
| FormulaWt. | 406.43 |
| IUPACName | 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one |
| Synonym | P529 |
| Appearance | WhiteCrystalPowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | P0246InfoSheetPDF |
|---|---|
| Brochures | PI3K-Akt-mTORCPathwayBooklet |
DalalM,Jacobs-ElN,NicholsonB,etal.SubconjunctivalPalomid529inthetreatmentofneovascularage-relatedmaculardegeneration.GraefesArchClinExpOphthalmol.2013Dec;251(12):2705-9.PMID:23689994.
XiangT,JiaY,SherrisD,etal.TargetingtheAkt/mTORpathwayinBrca1-deficientcancers.Oncogene.2011May26;30(21):2443-50.PMID:21242970.
XueQ,HopkinsB,PerruzziC,etal.Palomid529,anovelsmall-moleculedrug,isaTORC1/TORC2inhibitorthatreducestumorgrowth,tumorangiogenesis,andvascularpermeability.CancerRes.2008Nov15;68(22):9551-7.PMID:19010932.
